Fibrovein ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
279巨大静脈奇形(頚部口腔咽頭びまん性病変)2

279. 巨大静脈奇形(頚部口腔咽頭びまん性病変)


臨床試験数 : 15 薬物数 : 24 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 105
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-001455-37-NO
(EUCTR)
21/12/201101/06/2011Prospective randomized interventional study in patients with venous malformations.Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophysiological study of a subpopulation of patients with venous malformations. Venous malformation
MedDRA version: 13.1;Level: LLT;Classification code 10047229;Term: Venous malformation NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Bleomycin Baxter
Product Name: Bleomycin
Trade Name: Fibrovein 3%
Product Name: Fibrovein 3%
Department of Radiology, Oslo University Hospital, NorwayNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Norway
2NCT01347294
(ClinicalTrials.gov)
August 201111/4/2011Compare Two Different Sclerosing Agents in the Treatment of Venous MalformationsCompare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous MalformationsVenous MalformationDrug: Bleomycin;Drug: Fibrovein;Drug: Bleomycin + FibroveinOslo University HospitalNULLRecruiting12 Years80 YearsAll126Phase 4Norway